ScreenerHero

FRNM Freenome, Inc.

NAS · US · Healthcare · Diagnostics & Research · freenome.com
16.03USD-2.02%Mkt Cap: 1.72B $P/E: —

Freenome, Inc., a biotechnology company, develops blood-based screening tests to detect cancer in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligen…

Industry Peers

Diagnostics & Research
Screen all
TMO
Thermo Fisher Scientific Inc.
$244.79BUSDP/E 36.7
DHR
Danaher Corporation
$153.60BUSDP/E 38.9
NTRA
Natera, Inc.
$57.02BUSD
LONN
Lonza Group AG
$46.01BUSDP/E 38.3
A
Agilent Technologies, Inc.
$47.67BUSDP/E 33.4
WAT
Waters Corporation
$42.81BUSDP/E 110.4
IQV
IQVIA Holdings Inc.
$42.48BUSDP/E 32.1
ILMN
Illumina, Inc.
$40.43BUSDP/E 50.0
IDXX
IDEXX Laboratories, Inc.
$39.97BUSDP/E 35.6
MTD
Mettler-Toledo International Inc.
$30.73BUSDP/E 34.6
LH
Labcorp Holdings Inc.
$25.30BUSDP/E 25.8
DGX
Quest Diagnostics Incorporated
$25.06BUSDP/E 24.1
GH
Guardant Health, Inc.
$22.59BUSD
RVTY
Revvity, Inc.
$17.14BUSDP/E 73.5
MEDP
Medpace Holdings, Inc.
$16.87BUSDP/E 35.5
ERF
Eurofins Scientific SE
$14.23BUSDP/E 26.6
CRL
Charles River Laboratories International, Inc.
$14.34BUSD
ICLR
ICON Public Limited Company
$12.66BUSDP/E 172.7
BIM
bioMérieux S.A.
$10.35BUSDP/E 20.7
QGEN
Qiagen N.V.
$9.25BUSDP/E 22.7
HeadlineSourceTime
Older
Freenome (FRNM) Climbed, But What Is Driving Attention Now?

Freenome stock reaction and recent performance snapshot Freenome (FRNM) has drawn fresh investor attention following its recent share price move, with the stock last closing at $11.62. This puts the company’s market value at about $1.26b. Over the past month, Freenome’s share price return is 7.59%, while the past 3 months show a 2.83% gain. The stock’s 1 year total return stands at 9.93%, and the year to date performance reflects a decline of 10.62%. Freenome reported revenue of $34.24m,...

Simply Wall St.
Guardant Health, Stock Of The Day, Spikes After Hiking 2026 Outlook

Guardant Health is the IBD Stock Of The Day in a thriving market for colon cancer screening tests. GH stock popped nearly 7% in extended Thursday trading. Health and biotech stocks are acting well in the current market.

Investor's Business Daily